6月23日，生物制药公司药捷安康-B（02617.HK）在港交所主板挂牌上市，股价表现亮眼。开盘即大涨63.12%，报21.45港元，展现出投资者对这家创新药企的强烈兴趣。
药捷安康是一家专注于肿瘤、炎症及心脏代谢疾病小分子创新疗法的生物制药公司。公司核心产品Tinengotinib是一种独特的多靶点激酶（MTK）抑制剂，目前正进行两项关键性/注册临床试验，用于治疗胆管癌。这种创新型管线产品吸引了市场的高度关注。
此次IPO，药捷安康发行1528.1万股H股，每股发售价13.15港元，募集资金净额约1.61亿港元。公开发售部分获得约3420倍超额认购，反映出散户投资者的热烈追捧。值得注意的是，公司还吸引了包括江北医药、康方生物在内的五名基石投资者，合共认购1.3亿元公司股份，进一步增强了市场信心。
药捷安康的成功上市不仅反映了投资者对生物医药行业的持续看好，也凸显了市场对具有创新能力和强大研发实力的企业的青睐。随着公司进入资本市场，其在创新药物研发和商业化方面的潜力有望得到进一步释放。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.